1School of Pharmaceutical Sciences, University of Nottingham, University Park, Nottingham NG7 2RD, UK. martin.garnett@nottingham.ac.uk
Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment. Recent clinical successes demonstrate the effectiveness and selectivity of these targeted therapies, potentially ushering in a new era for chemotherapy.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: